Molecular modeling, spectrofluorimetric, and tandem mass spectrometric analysis reveal a competitive binding of amlodipine and rosuvastatin to plasma albumin: Insight into drug-drug interaction

Publication date: September 2019Source: Microchemical Journal, Volume 149Author(s): Mohamed Saleh Elgawish, Moustafa K. Soltan, Mahmoud M. SebaiyAbstractHyperlipidemia and hypertension are common co-morbidities and considerably increase the risk of cardiovascular complications. The combined treatment has been recommended for decades; the lipid-lowering agents, statins, and calcium channel blockers (CCBs) are commonly prescribed to control the situation. Hence, the development of sensitive assay is of great importance for pharmacokinetic and therapeutic drug monitoring of the combined drugs. Herein, simple and robust chromatography-electrospray ionization-tandem mass spectrometry LC-ESI/MS) method for simultaneous determination of rosuvastatin (ROS) and amlodipine (AML) in rat plasma was developed and fully validated using irbesartan (IRB) as an internal standard (IS). Specimen preparation involved acetonitrile (ACN)-induce protein precipitation followed by gradient elution using 6 mM ammonium formate plus 0.1% formic acid and ACN at a flow rate of 0.4 mL min−1on an Agilent Eclipse Plus ODS (4.6 × 100 mm, 3.5 μm) column. Multiple reaction monitoring in positive ion mode was used for quantitation of precursor ion production at m/z 409.2 → 294.1 & 238.2 for AML, 482.1 → 258.1 for ROS, and 492.1 → 206.9 for IRB. Linearity was observed in the range of 1–5000 ng mL−1 for AML and 1–10,000 ng mL−1 for ROS with detection limits (S/N ...
Source: Microchemical Journal - Category: Chemistry Source Type: research